Chip Diagnostics is developing the microDroplet Fluorescence Detector platform that can enable digital assays without bulky lab equipment

About Chip Diagnostics

Formed in 2016, Chip Diagonostics is a diagnostic device company based on David Issadore's groundbreaking research combining microelectronics, microfluidics, and nanomaterials that will enable digital assays with mobile devices.

Digital assays have enormous untapped potential for disease diagnostics, environmental surveillance, and biosafety monitoring, but are currently confined to laboratory settings due to the instrumentation necessary to generate, control, and measure tens of millions of independent droplets. Chip Diagnostics is developing the microDroplet Fluorescence Detector (µDFD), a mobile compatible device enabling digital assays by using an original microfluidic droplet production process, a high bandwidth of electronics, new sensing technology, and ubiquitously available cloud computing.

Fluorescence Detector Technology

Chip Diagnostics' microDroplet Fluorescence Detector (µDFD) is a hybrid microelectronic/microfluidic chip that 'unlocks' droplet based assays for mobile use, recording ultra-sensitive molecular measurements by performing millions of parallel experiments in picoliter droplets.

Ultrasensitive Detection

The detection of diseases or pathogen contamination is inherently challenging due to the complex, heterogeneous nature of disease and contaminations. To solve this challenge, our µDFD platform allows measurement of multiple molecular biomarkers for little marginal increase in cost with a sensitivity that matches gold standard technologies.

Flourescence Digitalization

Our µDFD platform generates and detects the fluorescence of millions of droplets per second (1000x faster than conventional approaches) only using a cell phone camera. Our key innovation is amplitude modulation of the signal from fluorescent droplets using distinct micro-patterning of the droplet signal, akin to the carrier frequency modulation used in cellular networks.

Microfluidic Parallelization

Current microfludic cell sensors are too slow by 100x to be meaningful in detecting the billions of cells in a sample of blood. Our µDFD platform increases microfluidic droplet production rate by 104x by incorporating thousands of droplet generators onto a single chip and by using on-chip delay lines to perform droplet PCR on >107 droplets/minute.

Chip Diagnostics is an emerging leader in exosome-based diagnostics, enabling minimally invasive disease detection and monitoring. We unlock the potential of liquid biopsy by fingerprinting diseases with organ-specific signatures, providing actionable clinical data.

Exosome-Based Liquid Biopsy Platform Technology Solution

Chip Diagnostics is commercializing an innovative hardware and data/AI informatics platform, used to develop novel, exosome-based biomarker signatures for early disease diagnostics and therapy management.

We developed a proprietary workflow to rapidly scan blood samples for trillions of exosomes individually to identify and interpret organ-specific exosome populations.

Our solutions enable extremely accurate “fingerprinting” of a broad range of diseases and their states, offering inexpensive, and less time and resource-intensive workflows across biopharma/drug discovery and diagnostics use cases.

Disease Indications – Human Studies

We are in the pre-commercial stage with our exosome-based assays for pancreatic cancer and traumatic brain injury, and in development – under commercial sponsorship – with an innovative lung cancer diagnosis and therapy response signature panel.

ExoTENPO uniquely enables disease interception at its earliest stage

Chip Diagnostics’ ExoTENPO is the technology showing the most promise to leverage liquid biopsy (blood) in the earliest disease stage, where currently (tissue) biopsies and imaging strategies dominate.

Exosomes – The Key to Unlocking Full Potential of Liquid Biopsies

Exosomes are a promising new biomarker in liquid biopsy. However, due to their small size and abundance, exosomes are difficult to isolate and interpret. Chip Diagnostics’ technology is the solution to this problem.

The Challenge

Tissues from the body, such as that from brain, lungs, or other vital organs, provide information about diseases, but are not easily accessible without invasive strategies such as biopsies.

Exosomes are shed into the blood from patients’ tissues, but have a diameter 100x smaller than a cell. Existing technology in biology can’t effectively handle the size. There is an enormous number of these vesicles in the blood. Capturing them requires sensors and sorters that are both very fast and very small.

Our Solution

Chip Diagnostics developed ExoTENPO to analyze a patient’s blood, from a routine draw in smaller amounts, to find specific vesicles in the blood coming from the tissues where doctors want to diagnose disease.

ExoTENPO Solution

RESOLUTION

ExoTENPO precisely isolates only tissue-specific exosomes from complex biological samples.

EASE OF USE

ExoTENPO is fully compatible with downstream workflows (NGS, PCR, ELISA).

CLINICAL VALUE

Our demonstrated AI approach drives the highest AUC outcomes in the earliest disease stages.

Making early cancer diagnosis possible